立方体使用与炎症性肠病的不太严重的疾病过程有关:全国性队列研究2006-2020年
Hamed Khalili1,2, Anders Forss3,4, Jonas Söderling3
1Clinical and Translation Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Inflammatory bowel diseases
|April 25, 2025
概括
对于性结肠炎 (UC) 和克罗恩病 (CD) 患者,他类药物显著降低了手术的风险. 他们还减少了UC患者的住院和发作,但不是CD患者.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 众所周知,他类药物可以降低炎症性肠病 (IBD) 的风险.
- 然而,它们对IBD疾病进展的影响仍然不清楚.
研究的目的:
- 调查他类药物使用与IBD疾病进展之间的关联.
- 评估他类药物对IBD相关手术,住院和疾病爆发的影响.
主要方法:
- 使用瑞典医疗保健登记册进行全国性队列研究 (2006-2020年).
- 包括19788名患有性结肠炎 (UC) 的成年人和12582名患有克罗恩病 (CD) 的成年人.
- 倾向性得分匹配比较了IBD结果的事件他类药物使用者与非使用者.
主要成果:
- 静止剂使用者在UC (aHR:0.55) 和CD (aHR:0.54) 两种情况下都显示出IBD相关手术的风险降低.
- 在UC患者中,他类药物与住院住院风险 (aHR:0.68) 和疾病爆发风险 (aHR:0.86) 的降低有关.
- 对于使用他类药物的CD患者来说,没有观察到住院治疗或发作的显著减少.
结论:
- 在UC和CD患者中,他类药物的使用与IBD相关手术风险降低有关.
- 药物还可以减少UC患者的住院和疾病爆发.
- 对于疾病进展,他类药物的益处在UC中显得比CD更明显.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
236
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
236
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80


